AngioDynamics Reports Widened Net Loss in Q3 2024 Amid Revenue Decline

Friday, 5 April 2024, 13:19
AngioDynamics Inc. (NASDAQ: ANGO) faced challenges in its third-quarter results as the company recorded a wider net loss compared to the previous year. Key financial indicators such as revenues and per-share losses highlight the impact of the company's performance. The CEO's comments on a recent settlement agreement and revenue projections provide valuable context for investors, shaping the company's path ahead.
https://store.livarava.com/456842bf-f34f-11ee-8966-87cc5c87fb08.jpg
AngioDynamics Reports Widened Net Loss in Q3 2024 Amid Revenue Decline

Financial Results Overview

AngioDynamics Inc. reported a widening net loss in Q3 2024, with significant declines in revenue and per-share earnings. The consecutive year-over-year loss signals underlying challenges in the company's operations.

Revenue Analysis

  • Third-quarter revenues dropped by 7% year-over-year to $75.2 million.
  • The company anticipates full-year 2024 revenues between $270 million and $275 million.

CEO Perspective

AngioDynamics' CEO, Jim Clemmer, highlighted a recent settlement with BD/Bard that will impact future growth strategies. Clemmer emphasized the need for continued focus on key growth areas to mitigate financial challenges.

The post ANGO Earnings: Highlights of AngioDynamics’ Q3 2024 results first appeared on AlphaStreet.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Related posts

Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe